The Benefits of Dual Inhibition of 5α Reductase
September 2006
in “
European Urology Supplements
”
TLDR Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
The document discussed the benefits of dual inhibition of 5α-reductase in managing benign prostatic hyperplasia (BPH), focusing on dutasteride, which inhibited both type I and type II 5α-reductase, leading to greater suppression of dihydrotestosterone (DHT) than finasteride, which only inhibited type II. In a study with 399 patients, dutasteride reduced DHT levels by 94.7% compared to 70.8% with finasteride and showed more rapid and significant improvements in symptoms and prostate volume reduction over 4 years. However, the document noted that direct comparative studies between dutasteride and finasteride were limited, leaving the question of definitive superiority unresolved.